Incidence of Dyspnea and Assessment of Cardiac and Pulmonary Function in Patients With Stable Coronary Artery Disease Receiving Ticagrelor, Clopidogrel, or Placebo in the ONSET/OFFSET Study
- 13 July 2010
- journal article
- research article
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 56 (3), 185-193
- https://doi.org/10.1016/j.jacc.2010.01.062
Abstract
No abstract availableKeywords
Funding Information
- Daiichi-Sankyo
- Novartis
- Schering-Plough
- Eli Lilly and Company
- AstraZeneca
- Medicines Company
This publication has 6 references indexed in Scilit:
- Ticagrelor versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2009
- Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP‐induced receptor signaling and platelet aggregationJournal of Thrombosis and Haemostasis, 2009
- Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared With Clopidogrel, in Patients With Non–ST-Segment Elevation Acute Coronary SyndromeJournal of the American College of Cardiology, 2007
- Biology and Pharmacology of the Platelet P2Y12 ReceptorCurrent Pharmaceutical Design, 2006
- Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirinEuropean Heart Journal, 2006
- Intravenous adenosine and dyspnea in humansJournal of Applied Physiology, 2005